Saba Capital Income & Opportunities Fund has announced plans for a merger with Saba Capital Income & Opportunities Fund II, pending shareholder approval. This strategic move is set to enhance the scale of assets and investment opportunities for the combined entity. Shareholders will have the opportunity to vote on this proposal during a special meeting scheduled for December 17, 2026.
The merger is part of a broader trend in the investment industry towards consolidation, aimed at achieving greater operational efficiencies and expanding investment strategies. The decision underscores Saba Capital's commitment to enhancing shareholder value through increased asset scale and diversification.
Background
Saba Capital Income & Opportunities Fund, which trades on the NYSE under the ticker BRW, is a closed-end management investment company. The fund focuses on generating income through investments in various financial instruments. The recent filing with the SEC, dated November 10, 2026, outlines the upcoming special meeting where shareholders will vote on the merger proposal.
What the Filing Says
The SEC filing indicates that the special meeting will take place via audio teleconference, allowing shareholders to participate without traveling. The primary agenda for the meeting is to approve the issuance of additional common shares in connection with the merger, as outlined in the Reorganization Agreement. The filing states, "The Board of Trustees recommends that you vote 'FOR' the Proposal." This highlights the board's confidence in the benefits of the merger.
Impact
The proposed merger is expected to impact both the shareholders of Saba Capital Income & Opportunities Fund and those of Saba Capital Income & Opportunities Fund II. The merger aims to create a larger combined fund that can leverage greater efficiencies and investment opportunities. The board believes that the merger will lead to improved market liquidity and a narrower trading discount of market price to net asset value per share.
What's Next
Following the special meeting on December 17, 2026, the outcome will determine the future structure of the funds. If approved, the merger is expected to occur in the first quarter of 2027. However, the filing notes that the merger is contingent upon receiving the necessary approvals from shareholders of both funds.
Read Next
Kura Oncology files for $150 million securities offering
Nomura ETF Trust II Files Amended Registration for ETF
Sukhatme Mayukh Amends Filing for Share Sale at Roivant
Gline Matthew amends filing to report share sale for taxes
Torti Frank Amends Form 144 for Share Sale of Roivant Sciences
Profusa Inc. Announces Special Meeting for Key Proposals









